InvestSMART

Rhythm Biosciences Limited (ASX: RHY) - Announcements

Current share price for RHY : $0.085 0.007 (7.61%)+

ASX company news and announcements for Rhythm Biosciences Limited (RHY) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Rhythm Biosciences Limited (RHY) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Rhythm Biosciences Limited (RHY), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Rhythm Biosciences Limited (RHY)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$30 First geneType Clinical Test Sale in South East Asia 26 Mar 2026 8:31AM $0.205 $0.085 fallen by 58.54%
$30 Application for quotation of securities - RHY 20 Mar 2026 4:52PM $0.200 $0.085 fallen by 57.50%
$30 Accelerating the Commercial Rollout of ColoSTAT 18 Mar 2026 8:36AM $0.210 $0.085 fallen by 59.52%
$30 Investor Webinar Presentation 18 Mar 2026 8:26AM $0.210 $0.085 fallen by 59.52%
$30 Application for quotation of securities - RHY 13 Mar 2026 12:47PM $0.220 $0.085 fallen by 61.36%
$30 Investor Webinar 12 Mar 2026 9:16AM $0.225 $0.085 fallen by 62.22%
$30 First ColoSTAT Clinical Test Sale 11 Mar 2026 8:28AM $0.200 $0.085 fallen by 57.50%
$30 NATA Accredits ColoSTAT Clinical Testing Service 9 Mar 2026 9:10AM $0.185 $0.085 fallen by 54.05%
$30 Application for quotation of securities - RHY 6 Mar 2026 10:07AM $0.190 $0.085 fallen by 55.26%
$30 RHY Executes SE Asian Genetype Distribution Agreement 4 Mar 2026 8:57AM $0.185 $0.085 fallen by 54.05%
$30 Cleansing Notice 27 Feb 2026 4:27PM $0.215 $0.085 fallen by 60.47%
$30 Application for quotation of securities - RHY 27 Feb 2026 4:22PM $0.215 $0.085 fallen by 60.47%
$30 Application for quotation of securities - RHY 27 Feb 2026 10:06AM $0.220 $0.085 fallen by 61.36%
$30 $5.5 million Secured for RHYO Options 27 Feb 2026 9:24AM $0.220 $0.085 fallen by 61.36%
$30 NHS England ColoSTAT Evaluation Commences 26 Feb 2026 9:11AM $0.225 $0.085 fallen by 62.22%
$30 Proposed issue of securities - RHY 25 Feb 2026 8:44AM $0.205 $0.085 fallen by 58.54%
$30 Exercise of RHYO Options underwritten for $4.5m to $6.0m 25 Feb 2026 8:43AM $0.205 $0.085 fallen by 58.54%
$30 Trading Halt 23 Feb 2026 9:44AM $0.205 $0.085 fallen by 58.54%
$30 Application for quotation of securities - RHY 20 Feb 2026 3:14PM $0.205 $0.085 fallen by 58.54%
$30 Half-Year Financial Report and Appendix 4D 18 Feb 2026 2:14PM $0.220 $0.085 fallen by 61.36%
$30 Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology 17 Feb 2026 8:39AM $0.205 $0.085 fallen by 58.54%
$30 Application for quotation of securities - RHY 16 Feb 2026 5:02PM $0.205 $0.085 fallen by 58.54%
$30 Investor Presentation 16 Feb 2026 9:23AM $0.210 $0.085 fallen by 59.52%
$30 ColoSTAT commercial deployment - First physician enrolled 11 Feb 2026 8:32AM $0.225 $0.085 fallen by 62.22%
$30 Letter to RHYO option holders 10 Feb 2026 12:22PM $0.225 $0.085 fallen by 62.22%

26 - 50 of 639 results

Page 2 of 26

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.